Canada markets closed

Eyenovia, Inc. (EYEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6900-0.0800 (-4.52%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.7700
Open1.7700
Bid1.6900 x 1000
Ask1.7000 x 900
Day's Range1.6500 - 1.7700
52 Week Range1.5900 - 6.6300
Volume491,642
Avg. Volume159,841
Market Cap57.82M
Beta (5Y Monthly)1.89
PE Ratio (TTM)N/A
EPS (TTM)-0.5380
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.33
  • GlobeNewswire

    Eyenovia Reports Second Quarter 2022 Financial Results

    Announced appointment of Michael Rowe as Chief Executive Officer and Board member Mydcombi™ NDA resubmission on track for the fourth quarter of 2022 Phase 3 VISION-2 study evaluating MicroLine as an on-demand treatment for improving near vision (presbyopia) progressing as planned; topline data expected in the third quarter of 2022 Company to host conference call and webcast today, August 10, at 4:30 pm ET NEW YORK, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a clinical stage

  • GlobeNewswire

    Eyenovia to Report Second Quarter 2022 Results on Wednesday, August 10

    Company to host an investor conference call and webcast at 4:30pm ET on that dayNEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, announced that the Company will release financial results for the second quarter ended June 30, 2022 on Wednesday, August 10, 2022, after the markets close. Following the release, Eyenovia management will host a conference call t

  • GlobeNewswire

    Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member

    Appointment of Mr. Rowe, Eyenovia’s current Chief Operating Officer, maintains continuity while bringing significant ophthalmic industry, operations and commercialization expertise to the CEO roleNEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced the appointment of current Chief Operating Officer Michael Rowe as the Company’s new C